Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
PUMA BIOTECHNOLOGY INC. (PBYI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.24, with a market capitalisation of $471.81M and a P/E ratio of 17.87. Over the past 52 weeks, its price has ranged from $4.30 to $9.74. This page covers its latest market performance, valuation, price trends and company information.
$471.81M | |
$9.15 | |
$279.37 | |
$1.60 | |
$9.14 | |
246.35K | |
341.64K | |
17.87 | |
$9.74 | |
$4.30 | |
-- | |
-- |
PUMA BIOTECHNOLOGY INC. (PBYI) is trading at $9.05 in pre-market trading as of 2026-09-15 23:49:00, down 1.00% ($0.09) from the previous close of $9.14
Pre-market trading shows how investors are pricing PBYI before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, PUMA BIOTECHNOLOGY INC. (PBYI) moved from $9.55 to $9.24, representing a decline of 3.24% ($0.31).
The stock traded between $8.85 and $9.64 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 292.93 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.9%
PBYI is currently trading at $9.24, placing it 90.9% of the way from its 52-week low of $4.30 to its 52-week high of $9.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 179 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PUMA BIOTECHNOLOGY INC. (PBYI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.